Sanofi-Aventis Recherche & Developpement

Address: 82 Avenue Raspail

Sponsor Overview

assignment

127

Specializations

Immune-Mediated Inflammatory Diseases

Clinical research includes ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, and systemic juvenile idiopathic arthritis, with additional interest in coeliac disease and chronic graft versus host disease.

Ulcerative colitis
Crohn's disease
Rheumatoid arthritis
Systemic lupus erythematosus
Chronic graft versus host disease

Research also extends to immune thrombocytopenia, autoimmune haemolytic anaemia, and other immune system diseases.

Dermatology and Allergic Disease

Studies cover atopic dermatitis, psoriasis, hidradenitis suppurativa, pruritus, and chronic rhinosinusitis with nasal polyps, alongside asthma and other respiratory tract diseases.

Atopic dermatitis
Psoriasis
Hidradenitis suppurativa
Asthma
Chronic rhinosinusitis with nasal polyps

Additional activity includes chronic obstructive pulmonary disease and bronchiectasis within broader respiratory disease research.

Haematology, Oncology, and Plasma Cell Disorders

Research spans multiple myeloma, plasma cell myeloma, relapsed/refractory multiple myeloma, acute myeloid leukemia, acute lymphocytic leukaemia, and myelodysplastic syndrome.

Multiple myeloma
Acute myeloid leukemia
Acute lymphocytic leukaemia
Myelodysplastic syndrome
Non-small cell lung cancer

Other areas include solid tumours, plasma cell myeloma recurrent, and light-chain amyloidosis.

Neurology and Neuromuscular Disorders

Clinical studies address multiple sclerosis, relapsing multiple sclerosis, progressive multiple sclerosis, amyotrophic lateral sclerosis, and chronic inflammatory demyelinating polyneuropathy.

Multiple sclerosis
Amyotrophic lateral sclerosis
Chronic inflammatory demyelinating polyneuropathy
Polyneuropathy
Neurological disorders

Research also includes inflammatory demyelinating polyradiculoneuropathy and broader nervous system diseases.

Metabolic, Genetic, and Rare Diseases

Work in this area includes type 1 diabetes mellitus, Fabry disease, Gaucher's disease type III, glycogen storage disease type II, and achondroplasia.

Type 1 diabetes mellitus
Fabry disease
Gaucher's disease type III
Achondroplasia
Congenital, hereditary and neonatal diseases

Additional interest is shown in hemophilia, transplant rejection, Usher's syndrome, and other nutritional and metabolic diseases.

Sponsored Trials

Trial Name	Country	Status
A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy	Austria Belgium Czechia Denmark Finland France Germany Hungary Italy Poland Slovenia Spain Sweden	Not Recruiting
A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment	Austria Czechia France Germany Hungary Italy Norway Poland Spain	Recruiting
A Phase 1 First-in-Human Study to Evaluate the Safety and Pharmacokinetics of SAR447754 in Healthy Adults and Adults with Moderate-to-Severe Atopic Dermatitis	Belgium Hungary Spain	Recruiting
A Phase 1, open-label, single-center study to determine the absorption, distribution, metabolism, and excretion of a single oral dose of SAR443820 containing microtracer [14C]-SAR443820 in healthy male participants	The Netherlands	Not Recruiting
A Phase 3 Non-inferiority Study Comparing Subcutaneous versus Intravenous Administration of Frexalimab in Adults with Multiple Sclerosis	Belgium Italy Spain	Recruiting
A Phase 3 Randomized Controlled Trial to Evaluate the Efficacy and Safety of Rilzabrutinib in Adults with Active IgG4-Related Disease	Belgium France Germany Italy Poland Spain Sweden The Netherlands	Recruiting
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis - EFC17559 / COAST1	France Germany Greece Poland	Not Recruiting
A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX	France Germany Greece Italy Poland Spain	Not Recruiting
A Phase I Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Duvakitug in Healthy Adult Participants	Germany	Not Recruiting
A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis	Bulgaria Czechia France Germany Hungary Italy Poland Romania Slovakia Spain The Netherlands	Not Recruiting

1–10 of 127

1 / 13

Data & Insights

science

Molecule Portfolio

Compounds under investigation

Exclusive Molecules

out of 87 total (28% not shared with other sponsors)

This sponsor works with 87 molecules, of which 24 are not being studied by other sponsors.

hub

Site Partnerships

Collaboration with research centres

63%

Return partnership rate

655 of 1032 sites collaborated multiple times

This sponsor has worked with 1032 sites across their trial portfolio.

Therapeutic Focus

1.
Immune System Diseases43 trials
322 other sponsors
2.
Respiratory Tract Diseases22 trials
277 other sponsors
3.
Neoplasms17 trials
853 other sponsors
4.
Nervous System Diseases10 trials
449 other sponsors
5.
Digestive System Diseases9 trials
280 other sponsors
6.
Skin and Connective Tissue Diseases9 trials
247 other sponsors
7.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities7 trials
165 other sponsors
8.
Hemic and Lymphatic Diseases4 trials
249 other sponsors
9.
Musculoskeletal Diseases3 trials
238 other sponsors
10.
Nutritional and Metabolic Diseases2 trials
211 other sponsors
11.
Eye Diseases1 trial
138 other sponsors

Partnered Research Centres

1032 centres

location_city

assignment32

1 Wojskowy Szpital Kliniczny Z Poliklinika samodzielny publiczny zakład opieki zdrowotnej W Lublinie

Address: Ul. Aleje Raclawickie 23, 20-049 Lublin

Learn morearrow_forward

location_city

assignment23

401 General Military Hospital Of Athens

Address: Panagioti Kanellopoulou Av 1, 115 25 Athens

Learn morearrow_forward

location_city

assignment12

424 Military General Training Hospital

Address: Ring Road, N. Efkarpia, 564 29 Thessaloniki

Learn morearrow_forward

location_city

assignment103

A.O.U. Policlinico G. Martino Di Messina

Address: Via Consolare Valeria N 1, 98124 Messina

Learn morearrow_forward

location_city

assignment335

Aalborg University Hospital

Address: Moelleparkvej 4, 9000 Aalborg

Learn morearrow_forward

location_city

assignment352

Aarhus University Hospital

Address: Palle Juul-Jensens Boulevard 99, 8200 Aarhus

Learn morearrow_forward

Page 1 of 172

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Sanofi-Aventis Recherche & Developpement.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.